NTRA Stock Overview
A diagnostics company, develops and commercializes molecular testing services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Natera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$167.26 |
| 52 Week High | US$171.95 |
| 52 Week Low | US$53.62 |
| Beta | 1.53 |
| 11 Month Change | 40.97% |
| 3 Month Change | 36.31% |
| 1 Year Change | 204.11% |
| 33 Year Change | 76.70% |
| 5 Year Change | 358.37% |
| Change since IPO | 635.53% |
Recent News & Updates
Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%
Nov 19
Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158
Nov 15Recent updates
Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%
Nov 19Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158
Nov 15Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
Oct 31Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price
Sep 18Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?
Jul 05Natera: Overdue For A Breather
Jun 03Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119
May 12Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?
Mar 30Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
Mar 22Is Natera (NASDAQ:NTRA) A Risky Investment?
Mar 03Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)
Dec 11Is Natera (NASDAQ:NTRA) A Risky Investment?
Nov 10Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate
Aug 07Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?
May 16Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement
Apr 18Shareholder Returns
| NTRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.5% | -3.7% | 0.3% |
| 1Y | 204.1% | 15.2% | 31.1% |
Return vs Industry: NTRA exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: NTRA exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NTRA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NTRA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 3,288 | Steve Chapman | www.natera.com |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
Natera, Inc. Fundamentals Summary
| NTRA fundamental statistics | |
|---|---|
| Market cap | US$22.36b |
| Earnings (TTM) | -US$214.69m |
| Revenue (TTM) | US$1.53b |
14.4x
P/S Ratio-102.9x
P/E RatioIs NTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTRA income statement (TTM) | |
|---|---|
| Revenue | US$1.53b |
| Cost of Revenue | US$648.58m |
| Gross Profit | US$883.38m |
| Other Expenses | US$1.10b |
| Earnings | -US$214.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 57.66% |
| Net Profit Margin | -14.01% |
| Debt/Equity Ratio | 41.8% |
How did NTRA perform over the long term?
See historical performance and comparison